We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+6.32%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$5.22B
AUM Growth
Cap. Flow
+$5.1B
Cap. Flow %
97.85%
Top 10 Hldgs %
41.69%
Holding
82
New
81
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 14.85%
2 Consumer Staples 9.94%
3 Communication Services 9.9%
4 Industrials 9.67%
5 Real Estate 9.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OMTH
51
DELISTED
OMTHERA PHARMACEUTICALS INC COM STK (DE)
OMTH
$16M 0.31%
+1,200,000
New +$11.7M
HK
52
DELISTED
Halcon Resources Corporation
HK
$14M 0.27%
+14,354
New +$15.3M
HTSI
53
DELISTED
HARRIS TEETER SUPERMARKETS INC COM STK (NC)
HTSI
$10.6M 0.2%
+225,408
New +$10M
PCO
54
DELISTED
Pendrell Corporation - Class A
PCO
$10.5M 0.2%
+3,997
New +$8.53M
ARB
55
DELISTED
ARBITRON INC (NEW)
ARB
$10.2M 0.2%
+220,000
New +$10.3M
OMX
56
DELISTED
OFFICEMAX INCORPORATED
OMX
$8.8M 0.17%
+860,700
New +$9.96M
PBY
57
DELISTED
PEP BOYS MANNY MOE& JACK
PBY
$8.52M 0.16%
+735,810
New +$8.64M
RPRX
58
DELISTED
Repros Therapeutics Inc.
RPRX
$7.9M 0.15%
+428,000
New +$7.56M
MACK
59
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$7.18M 0.14%
+135,684
New +$5.95M
CIM
60
Chimera Investment
CIM
$964M
$6.92M 0.13%
+153,667
New +$7.3M
KMI.WS
61
DELISTED
Kinder Morgan Inc
KMI.WS
$6.81M 0.13%
+1,330,000
New +$7.29M
ICUI icon
62
ICU Medical
ICUI
$4.57B
$5.98M 0.11%
+83,000
New +$5.49M
OREX
63
DELISTED
Orexigen Therapeutics, Inc.
OREX
$5.56M 0.11%
+95,000
New +$5.84M
HZNP
64
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.47M 0.1%
+2,223,071
New +$5.33M
ONXX
65
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
$5.43M 0.1%
+62,500
New +$5.75M
GWPH
66
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.93M 0.09%
+560,000
New +$4.96M
ZTS icon
67
Zoetis
ZTS
$32.1B
$4.7M 0.09%
+152,279
New +$4.93M
TTM
68
DELISTED
Tata Motors Limited
TTM
$4.63M 0.09%
+197,514
New +$5.12M
ANAC
69
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$3.56M 0.07%
+637,500
New +$3.86M
ARQL
70
DELISTED
Arqule Inc
ARQL
$3.4M 0.07%
+1,464,699
New +$3.95M
LPS
71
DELISTED
LENDER PROCESSING SERVICES INC
LPS
$3.38M 0.06%
+104,475
New +$3.04M
STML
72
DELISTED
Stemline Therapeutics, Inc.
STML
$3.22M 0.06%
+135,000
New +$2.15M
GDI
73
DELISTED
GARDNER DENVER,INC
GDI
$2.63M 0.05%
+35,000
New +$2.63M
SVN
74
DELISTED
7 Days Group Holdings Ltd
SVN
$2.62M 0.05%
+190,000
New +$2.59M
GCVRZ
75
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$2.51M 0.05%
+1,320,000
New +$2.32M

Similar funds

Thomas Steyer's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Thomas Steyer, which disclosed 82 positions worth $5.22B. Its ten largest holdings account for 42% of the portfolio.

Its largest position is NEWS CORPORATION CL-A: 9,255,000 shares worth $302M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 15% of assets, followed by Consumer Staples and Communication Services.

  • Thomas Steyer's largest Q2 2013 buy was NEWS CORPORATION CL-A: 9,255,000 shares worth $302M.
  • Thomas Steyer's ten largest holdings make up 42% of its $5.22B portfolio in Q2 2013.
  • Thomas Steyer disclosed 82 positions in Q2 2013, its first 13F filing on record.

Based on Farallon Capital Management's 13F filing for Q2 2013, filed 14 Aug 2013.